tigilanol tiglate

Phase 2Small molecule

QQBiotics Group Limited

tigilanol tiglate is one of 87 small molecule programs targeting Head and Neck Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head and Neck CancerActive, not recruiting

Soft Tissue SarcomaRecruiting

Head and Neck CancerPhase 2

Active, not recruiting

Soft Tissue SarcomaPhase 2

Recruiting

Competition

Competitive Landscape

64 competitors in Soft Tissue Sarcoma

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

34 2

Adriamycin

Pfizer

Phase 3

27 3

Idamycin

Pfizer

Approved

—4

Ifex

BBaxter Healthcare Corporation

Phase 3

32 5

Gemzar

Johnson & Johnson

Phase 3

11 6

Yondelis

AApotex Inc.

Phase 3

16 7

Neulasta

Amgen

Phase 3

3 8

Ellence

Pfizer

Phase 3

2 9

Cytoxan

BBaxter Healthcare Corporation

Phase 3

8 10

Opdivo

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Soft Tissue Sarcoma

NCT05755113

Clinical

Trials by Indication[1]

Melanoma2 trials

A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

Terminated·QQBiotics Group Limited·Phase 1/2·NCT04834973·3 enrolled

A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma

Terminated·QQBiotics Group Limited·Phase 2·NCT05234437·1 enrolled

Soft Tissue Sarcoma1 trial

A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma

Recruiting·QQBiotics Group Limited·Phase 2·NCT05755113·40 enrolled

Head and Neck Cancer1 trial

A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

Active, not recruiting·QQBiotics Group Limited·Phase 2·NCT05608876·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for tigilanol tiglate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tigilanol tiglate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tigilanol tiglate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — QBiotics Group Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: QQBiotics Group Limited

tigilanol tiglate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Melanoma2 trials

Soft Tissue Sarcoma1 trial

Head and Neck Cancer1 trial

References

Drug Info

Quick Facts

Related News